suffered from flu-like symptoms and developed a dry, pruritic rash on her upper limbs which resolved over a week. Day 6 after the second infusion the patient reported aching of the low back and lower limbs, with numbness and paresthesia of the toes, and burning of the feet. Examination revealed a tandem gait ataxia, reduced power, and loss of light touch with diminished pain, proprioception, and vibration sense to the level of the ankles. Her lower limbs were areflexic, with nonresponsive plantars and a positive Romberg sign. Nerve conduction studies revealed a severe sensory motor neuropathy. Investigations including antinuclear antibodies (ANA), extractable nucleic acid (ENA), erythrocyte sedimentary rate (ESR), anti neutrophil cytoplasmic antibody (ANCA), double stranded DNA (dsDNA), anti-neuronal nucleus 1 (anti-Hu), anti-neuronal nucleus 2 (anti-Ri), purkinje cell antibody (anti-Yo), purkinje cell antibody (anti-PCA-2), thyroid stimulating hormone (TSH), glucose, vitamin B 12 , folate, anti tissue transglutaminase (anti-TTG), and chest computed tomography (CT) were within normal limits. Serum protein electrophoresis on several occasions over 6 months demonstrated an IgG kappa monoclonal band of Ͻ2.0 g/L. The patient's clinical presentation was consistent with a generalized axonal neuropathy, and following withdrawal of the anti-TNF␣ agent her neurological symptoms and signs resolved over a period of 4 months.
The time course of this adverse event makes it very likely that it was due to the infliximab therapy. Axonal polyneuropathy has been reported with TNF␣ antibody treatment of rheumatoid arthritis but as far as we are aware it has not been reported with treatment of CD or ulcerative colitis. 2 Despite the high levels of TNF␣ found in the cerebral spinal fluid and brain plaques of multiple sclerosis patients, anti-TNF␣ therapy is not effective in this condition. In a randomized, placebo-controlled trial involving 168 multiple sclerosis patients, Lenercept, a p55 TNF receptor fusion protein, resulted in increased disease activity with higher relapse rates. 3 Moreover, infliximab therapy is associated with an increased number of new gadolinium-enhancing lesions on magnetic resonance imaging (MRI) in multiple sclerosis patients. 4 Case reports of peripheral neurological complications arising in patients with rheumatoid arthritis include Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy with conduction block, and mononeuritis simplex/multiplex. 2, [5] [6] [7] In summary, central and peripheral neuropathies are rare but recognized side effects of TNF␣ monoclonal antibody therapy. However, neuropathies are not commonly mentioned with regard to complications of TNF␣ monoclonal antibody treatment in the IBD literature. Axonal neuropathy in particular has not been reported with TNF␣ monoclonal antibody treatment of IBD, and we draw this to the attention of our gastroenterology colleagues. 
